Michael D Dale's Insider Trades & SAST Disclosures
Michael D Dale's most recent trade in Axogen Inc. was a trade of 176,300 Restricted Stock Units done . Disclosure was reported to the exchange on March 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael D Dale.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axogen Inc. | Michael J. Dale | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2025 | 176,300 | 176,300 | - | - | Restricted Stock Units | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 1,182 | 2,364 | - | - | Restricted Stock Units | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 1,182 | 12,572 (0%) | 0% | - | Common Stock | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 1,017 | 11,743 (0%) | 0% | - | Common Stock | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2025 | 1,017 | 1,016 | - | - | Restricted Stock Units | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.98 per share. | 24 Feb 2025 | 410 | 12,162 (0%) | 0% | 16.0 | 6,552 | Common Stock |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.98 per share. | 24 Feb 2025 | 353 | 11,390 (0%) | 0% | 16.0 | 5,641 | Common Stock |
| Axogen Inc. | Michael D. Dale | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 450,000 | 450,000 | - | - | Performance Stock Units | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,546 | 3,546 | - | - | Restricted Stock Units | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,016 | 11,016 (0%) | 0% | - | Common Stock | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 1,016 | 2,033 | - | - | Restricted Stock Units | |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. | 01 Mar 2024 | 290 | 10,726 (0%) | 0% | 12.7 | 3,680 | Common Stock |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Purchase of securities on an exchange or from another person at price $ 9.75 per share. | 03 May 2023 | 10,000 | 10,000 (0%) | 0% | 9.8 | 97,500 | Common Stock |
| Crossfirst Bankshares Inc | Michael J. Daley | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 1000.00 per share. | 29 Mar 2023 | 100 | 100 | - | 1000 | 100,000 | Series A Non-Cumulative Perpetual Preferred Stock |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 4,942 | 46,342 (0%) | 0% | 99.8 | 493,063 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 100.70 per share. | 28 Feb 2023 | 1,209 | 45,133 (0%) | 0% | 100.7 | 121,746 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 37,483 | 37,483 | - | - | Option (right to buy) | |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 9,504 | 51,284 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 117.00 per share. | 08 Mar 2022 | 4,000 | 41,780 (0%) | 0% | 117.0 | 468,001 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 4,505 | 46,833 (0%) | 0% | 122.4 | 551,457 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.15 per share. | 28 Feb 2022 | 1,053 | 45,780 (0%) | 0% | 118.2 | 124,412 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 54,280 | 54,280 | - | - | Option (right to buy) | |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 11,647 | 51,338 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.33 per share. | 28 Jul 2021 | 17,600 | 39,691 (0%) | 0% | 120.3 | 2,117,882 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 17,600 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.72 per share. | 28 Jul 2021 | 17,600 | 57,291 (0%) | 0% | 50.7 | 892,672 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 4,000 | 41,166 (0%) | 0% | 121.6 | 486,320 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.61 per share. | 26 Feb 2021 | 1,475 | 39,691 (0%) | 0% | 120.6 | 177,900 | Common shares without par value |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 53,326 | 53,326 | - | - | Option (right to buy) | |
| Abbott Laboratories | Michael D. Dale | SENIOR VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 10,403 | 45,166 (0%) | 0% | 0 | Common shares without par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges